Business Update21 Aug 2025, 02:19 pm
Concord Biotech's API Facility in Limbassi Successfully Passes EU GMP Inspection
AI Summary
Concord Biotech Ltd. has announced the successful completion of the European Union Good Manufacturing Practice (EU-GMP) inspection at their Active Pharmaceutical Ingredients (API) manufacturing facility in Limbassi. The inspection took place from August 18, 2025, to August 21, 2025, and the approval will enable Concord to explore commercial opportunities across various EU territories and other regulated geographies. This achievement reflects Concord's commitment to quality, safety, and regulatory compliance, reinforcing their global presence and growth trajectory.
Key Highlights
- Concord Biotech's API facility in Limbassi successfully passes EU GMP inspection
- EU-GMP approval paves the way for expanding Concord's footprint into new international markets
- Approval enables Concord to explore commercial opportunities across various EU territories and other regulated geographies
- This milestone highlights Concord's commitment to the highest standards of quality, safety, and regulatory compliance
- The achievement reflects Concord's dedication to operational excellence and alignment with global regulatory expectations